Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled date : 2021 - 05 - 24 save search
Insights on the Oncology/Cancer Drugs Global Market to 2027 - Opportunity Analysis and Industry Forecasts
Published: 2021-05-24 (Crawled : 20:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.07%
H: 0.21%
C: -0.35%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.07%
H: 0.33%
C: -0.86%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.05%
H: 0.03%
C: -1.22%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.24%
H: 0.05%
C: -0.73%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.44%
H: 0.44%
C: -1.89%
cancer drug
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Published: 2021-05-24 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
disease risankizumab
The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
Published: 2021-05-24 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
results dermatitis phase 3 atopic dermatitis lancet
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.